Kraig Biocraft Laboratories Completes Closeout of $8 Million Financing, Extinguishing All convertible Debentures with Yorkville Advisors

Ann Arbor, MI., November 21, 2022 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that it has completed the debt-to-equity conversion on $8 million of convertible debentures with Yorkville Advisors. This closeout comes several months ahead of schedule and positions the Company to enter 2023 without any convertible debt obligations to Yorkville Advisors.

The Company would like to thank Yorkville Advisors and Maxim Group for supporting its vision to transform the textile markets with large-scale production of cost-effective and eco-responsible spider silk. 

Kraig Labs currently has more than $4.5 million of deployable liquid assets and will continue to use this capital to develop end-market products and strengthen the supply chain creating its revolutionary spider silk technologies. 

“While this financing has been a critical element of our transition to commercialization, we are pleased to report that we have eliminated the burden of this debt and enter the holiday season in a solid financial position. We continue to judiciously deploy this capital to build out our spider silk production capacity. Our focus now is on increasing that production, including further strengthening our production infrastructure. An important part of that program is the planned rollout of new hybrids. Our target remains metric ton production,” said CEO Kim Thompson.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories poised to Close Out Yorkville Convertible Debenture with Strongest Financial Position in Corporate History

Ann Arbor, MI– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that it has nearly closed out its $8 million in convertible debenture with Yorkville Advisors. Over the last 23 months, the Company has converted more than 98% of this debt to equity. Kraig Labs remains in one of the strongest financial positions in the Company’s history, with more than $4.5 million in liquid assets and a remaining debt balance to Yorkville of only $150,000. 

The capital raised through this financing has been deployed in building out the Company’s in-house production and laboratory facilities in Vietnam, expanding the capabilities and research focus of our US-based R&D center, and funding the Company’s work with third-party production partners to scale up spider silk production. Looking forward, the Company expects to continue investing in the scale-up of production capacity, pioneering innovations in spider silk technologies, and bringing products to end markets through direct sales and strategic partnerships.

“Due to the significant progress that we made in securing our new production partnership program, which is designed to allow Kraig Labs to meet anticipated demand without the previous model’s intense capital investments, these funds provide us the flexibility that we need to continue to drive growth and strengthen our operations from R&D through finished products,” said Company COO, Jon Rice.

“With more than $4.5 million of immediately deployable capital and having nearly eliminated the balance on this debit financing, Kraig Labs has never been in a stronger financial position. We will continue to strategically invest this capital in ramping production through our in-house capacity and partnership with our third-party contractor as well as launch the next generations of hybrid spider silk technologies,” Rice concluded.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories Engages Textile Expert to Develop New Innovative Yarns and Fabrics Applications for Dragon Silk™  

Ann Arbor, MI., – September 12, 2022 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that it has contracted Jeff Dorton, a top textile expert to assist the Company in developing new and innovative yarns and fabrics utilizing Dragon Silk™.

Kraig Labs is leveraging Mr. Dorton’s expertise and proven record of innovation in textiles to create new and exciting composite yarns and fabrics utilizing spider silk. The initial customer for these yarns and fabrics will be Spydasilk Enterprises, the Company’s joint venture apparel brand, headquartered in Singapore. Following the launch of Spydasilk apparel, the Company plans to expand collaboration with Mr. Dorton to create several additional yarns and textiles, for applications spanning the performance and luxury textiles market and beyond.

Mr. Dorton brings a passion for material development, a proven track record of innovation, and a wealth of experience working with some of the best textile mills worldwide. He has led some of those most disruptive innovations in next-generation textiles that permeate the performance wear segment.

Utilizing his extensive network of mills and spinners around the globe, Mr. Dorton is currently working to drive the manufacture of the first spider silk fabrics.

“I have known Jeff since his time with The North Face, and I am thrilled to partner with him to create Kraig Labs’ first custom yarns and fabrics. Jeff is a highly regarded textile expert with a storied history of developing new textile technologies. He has directed key initiatives for some of the planet’s biggest brands, and we can’t wait to see what we can do together. While his ability to develop high-performance yarns and fabrics may be unmatched, we share Jeff’s passion for sustainability and textiles that are functional and desirable,” stated Company COO Jon Rice.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Jeff Dorton

Dorton is Vice President of Product Development and Material Innovation at LifeLabs Design. Previously he directed material innovation efforts for The North Face and Under Armour.

Dorton’s career highlights include developing Intellectual Property in fabric and insulation commercialized by leading performance wear brands around the globe. He has balanced this work in innovation with a solid commitment to environmental responsibility and drive to sustainability. Dorton led initial efforts to develop Nano spun membrane called FutureLight, the most advanced fabric and largest commercial launch in The North Face’s (TNF) history. Dorton expanded the franchise offering of “Thermoball” insulation through construction and material innovation for TNF. He coordinated with the sustainability team at VF Corporation to create the Responsible Down Standard that was later gifted to Textile Exchange to ensure ethical and sustainable sourcing for natural insulations. Dorton assisted in moving the entire supply chain at TNF to a more eco-friendly C0 DWR finish and shifted over 80% of fabrics into recycled content.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories Expands Operational Footprint in Vietnam

Ann Arbor, Michigan., – August 17, 2022– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that the Company has now been granted a business license to begin operations in Lam Dong Province. 

The newly established business license and facility in Lam Dong Province are part of the Company’s expansion into the Vietnamese highlands, the center of silk production in Vietnam. The highlands of Lam Dong Province offer temperate climates ideal for silkworm rearing and ready access to the cocoon and silk spinning facilities currently producing several hundred metric tons of mundane silk per year. 

In June, management from Kraig Labs traveled to Lam Dong for meetings with officials from the Lam Dong Agro-Forestry Research Experiment Center (LAREC) to assess the opportunities to expand silk production into the province and to tour the regional support infrastructure.   The LAREC operates as the authority in Vietnamese sericulture, maintaining 47 unique species of Vietnamese silkworms. The LAREC has developed multiple varieties of mulberry, including S7-CB, which has doubled production yields, from about 25-30 metric tons of foliage per hectare, for standard mulberry, to 50-60 tons of foliage per hectare, for the S7-CB mulberry strains. Kraig Labs planted with S7-CB mulberry at its facilities in Quang Nam, which has resulted in similar improvements.

The Company’s Vietnamese headquarters will remain in Quang Nam at its breeding and production center. This facility was recently featured as part of the Company’s behind-the-scenes video series, www.kraiglabs.com/videos. The Quang Nam facility is designed to produce and supply all of the Company’s proprietary silkworm eggs for in-house and 3rd party contract manufacturing.

“Lam Dong is the center of silk production in Vietnam. We are pleased to report that, with the granting of this business license, Kraig Labs and our specialized spider silk silkworm technologies are now being woven into the proud history and bright future of Vietnamese sericulture,” said Company COO Jon Rice.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk-based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could,” “will” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories Posts Behind the Scenes Look into the Laboratory R&D Processes for Creating Recombinant Spider Silk

Ann Arbor, Michigan., – August 4, 2022– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces the release of the second behind the scenes look into its recombinant spider silk production operations. This video brings the viewer inside the laboratories at its R&D facility in the U.S. and its quality control lab at its production facility in Vietnam. 

This video tour edition highlights the laboratory facilities and the team of dedicated researchers and scientists creating and commercializing the world’s first cost-effective and eco-responsible spider silk.

“Our research and quality assurance teams are leading the way, creating and commercializing some of the most amazing materials on earth,” said Company COO Jon Rice.

Interested viewers can find the video at www.kraiglabs.com/videos or through the Company’s YouTube Channel https://youtu.be/xX6z_e7gyvA, where they can subscribe to be notified of future video releases in this series.

In upcoming video releases, the Company expects to bring viewers along for tours inside the rearing and breeding operations and the opportunity to meet some of the team creating tomorrow’s super fibers.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk-based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could,” “will” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories Apparel Brand SpydaSilk Attends Largest International Textile and Garment Expo in Vietnam

Ann Arbor, Michigan., – August 1, 2022– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that representatives of its apparel brand SpydaSilkTM attended Vietnam’s premiere textile and garment industry exhibition, SaigonTex.

Since 1990, SaigonTex has brought together the largest collection of producers, suppliers, and buyers from Europe and Asia in the textile, fabric, and garment industry. Last week’s exhibition marked the event’s first return since 2019 after two years of COVID-19-related cancellations.   

The SpydaSilk team attended the Expo as part of its efforts to grow its network of suppliers. The team is working quickly to identify and partner with industry leaders capable of creating one-of-a-kind customer yarns and fabrics built upon Kraig Labs’ recombinant spider silk technologies. These new exclusive yarns and fabrics will be the foundation of SpydaSilk’s brand identity.    

“We are happy to see the return of SaigonTex, Vietnam’s premiere textile exhibition. The re-opening of this major international exhibition is evidence that the textile industry is roaring back. This event was a great opportunity for members of our SpydaSilk team to network with many new potential production partners as we work towards the first apparel launch,” said Company COO Jon Rice.

The Company expects to release the second video in its behind-the-scenes series taking viewers inside its spider silk production facilities next week. This episode will bring you inside the R&D labs at Kraig and Prodigy as the team works to create tomorrow’s super materials and monitors the performance and quality of current Dragon SilkTM production.

For those who missed the first episode in this video series, it can be found at www.kraiglabs.com/videos or through the Company’s YouTube Channel https://youtu.be/qeM2hzXbtRM, where viewers can subscribe to be notified of future video releases in this series.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk-based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “will”, “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories Releases First Behind the Scenes Look into the Production of Recombinant Spider Silk

Ann Arbor, Michigan., – July 20, 2022– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces the release of a behind the scenes look into its silkworm breeding facility in Vietnam. This video is the first in a series designed to bring the viewer inside the Company’s recombinant spider silk production operations. 

This video tour edition highlights the breeding and egg production center that the Company established in Vietnam, to support in-house and third-party contract manufacturing of its eco-responsible and cost-effective spider silk.

Operated by its wholly owned Vietnamese subsidiary, the Company believes that this facility is now equipped to meet the production demand for its proprietary specialized spider silk silkworm eggs through 2025 and has the capacity to expand far beyond that.

“Our team has built out what we believe to be one of the most advanced silkworm breeding facilities in the world. We are excited to share these first behind-the-scenes looks into our operations and to bring the viewers along on this incredible journey bringing our eco-responsible cost-effective spider silk to the global consumer markets,” said Company COO Jon Rice.

Interested viewers can find the video at www.kraiglabs.com/videos or through the Company’s YouTube Channel https://youtu.be/qeM2hzXbtRM, where they can subscribe to be notified of future video releases in this series.

In upcoming video releases, the Company expects to bring viewers along for tours inside the R&D and quality control labs as well as the feeding, rearing, and breeding operations.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk-based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories Enters Next Phase of Business Plan, Signs Deal with Contract Manufacturer to Produce Metric Tons of Recombinant Spider Silk

Ann Arbor, Michigan., – July 18, 2022– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces the signing of its first 3rd party production contract for large scale manufacturing of the Company’s recombinant spider silk. The Company expects to immediately begin operations with this contractor producing hundreds of kilograms of spider silk per month and to achieve production levels reaching multiple metric tons of spider silk per month as early as the first quarter of 2023. The contractor is in possession of the Company’s specialized eggs and anticipates a 90-day ramp-up for the first deliveries under the contract.

Pilot testing with this contractor during the first two quarters of 2022 demonstrated the capacity and expertise of this manufacturer to operate at a large scale and with excellent quality.

Under the contract terms, Kraig Labs will become a minority owner of the silk producer. Kraig Labs will have complete access to the manufacturer’s financial records and an onsite presence to ensure the proper handling and security of the Company’s propriety spider silk technology.

“Our business model was designed to leverage the existing silk production infrastructure. The signing of this agreement rapidly expands our access into that production network and brings us to the next critical stage in our business plan,” said Company COO Jon Rice. “Working with this contract manufacturer, we will soon be ready to deliver metric tons of eco-responsible and cost-effective spider silk to the consumer markets.”

In the coming days, the Company plans to release the first in a series of behind-the-scenes videos looking into its operations in Vietnam and the commercialization of its spider silk materials.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories Introduces New, Enhanced Line of Dragon Silk Silkworms for Commercial Production

Ann Arbor, MI – July 6, 2022– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that it has produced several new lines of larger hybrid Dragon SilkTM silkworms for its production operations in Vietnam. These new breeds of silkworms were explicitly created for large-scale production. 

With a larger cocoon and longer silk filament, these optimized Dragon Silk breeds reduce production costs and increase throughput.

The new breeds were created using a process of hybridization, combining the best properties of Dragon Silk with the best practices in silkworm breeding to improve the size and robustness of the silkworm strain. Commonly used in commercial mundane silk production, the process of creating these production hybrid silkworms delivers between 30-100% larger silk cocoons than non-hybridized silkworms.

The Company first began the development of large cocoon hybrids in 2018. The success of that effort is the foundation of today’s announcement and the rollout of this technology into production. Commercializing this technology required the Company to develop multiple strains of Dragon Silk hybrids that, when paired together, deliver a consistent and scalable large cocoon production platform.

“The hybridization program was a key part of the Company’s technology roadmap and something our R&D team has been quietly working on behind the scenes,” said Company COO Jon Rice. “Today, we announce that this technology is in the factory. This technology will lower our operating costs from rearing all the way through silk reeling and spinning. Over the coming months, our production team will transition egg production to this new, larger Dragon Silk line.”

Accelerating the transition of these new larger breeds of Dragon Silk to production was driven by the Company’s success with 3rd party contract production and our rapidly growing demand for increased quantities of Dragon Silk.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories Takes Next Step in Launching Spydasilk Apparel Brand

Ann Arbor, MI – June 27, 2022– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that, in collaboration with its joint venture partner Kings Group, the Company has selected a high-quality garment manufacturer to produce Spydasilk’sTM first apparel line.

Over the course of multiple meetings between Kraig Labs, Kings Group, and the garment manufacturer, conducted while the Company’s COO was in Vietnam this month, the Company finalized its manufacturer choice for the first apparel launch under the SpydasilkTM brand. 

The manufacturer selected has demonstrated its capacity and technical ability to deliver on Spydasilk’s vision for apparel that blends performance and elegance with its exclusive spider silk materials. With more than 20 years in business and its strong ties to Vietnam’s entire textile supply chain, this producer can leverage the capabilities of the best mills to bring the Spydailk brand to life. 

In partnership with Kings Group, the Company has already delivered its recombinant spider silk yarn and a non-spider silk fabric swatch for use in developing a brand new fabric built upon the performance and feel of the Company’s spider silk.

“Bringing the first products built on our spider silk technology to life is a critical step we are taking simultaneously with our planned increase in production through third-party contractors,” said Company COO, Jon Rice. “The network we have assembled to launch Spydasilk brings together top textile science, fashion, marketing, and branding experts. Our vision for the mass production and distribution of products built upon the amazing capabilities of spider silk is now quickly becoming a reality.”

Kraig Labs and Kings Group are simultaneously developing an accelerated product launch plan, including media, marketing, sales, and distribution systems for this first direct-to-consumer apparel launch.

The Company expects to continue to provide additional details and updates on the rapid advancements it is making under its business plan. Further information will be shared in press releases on advancements in production, quality control, and end market products over the coming days and weeks.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .